Search Results - "Fagnano, E"

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells by Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

“…Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many…”
Get full text

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells by Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

“…This corrects the article DOI: 10.1038/leu.2016.352…”
Get full text

A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model by Cheadle, E, Lipowska-Bhalla, G, Fagnano, E, Klein, C, Dovedi, S, Honeychurch, J, Illidge, T

Get full text

910 - A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model by Cheadle, E., Lipowska-Bhalla, G., Fagnano, E., Klein, C., Dovedi, S., Honeychurch, J., Illidge, T.

Get full text

Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells by Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

“…Correction to: Leukemia (2017) 31, 1611–1621; doi:10.1038/leu.2016.352; published online 3 January 2017 Following the publication of this article, it was noted…”
Get full text